Results 91 to 100 of about 6,571 (189)

Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes

, 2008
Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for the rapid degradation of circulating glucagon-like peptide-1 (GLP-1).
He, Y-L, Dunning, B E, Kelley, D E, Yu, T, Holst, Jens Juul, Ligueros-Saylan, M, Deacon, C F, Leone-Jones, A, Foley, J E   +8 more
core   +1 more source

Comparative Effectiveness and Safety of Acarbose and Vildagliptin in Type 2 Diabetes Management: A Real-World Observational Study in an Indian Population

Clinical Diabetology
OBJECTIVE: To evaluate and compare the real-world effectiveness and safety profiles of Acarbose and Vildagliptin in patients with type 2 diabetes (T2D), with an additional focus on their impacts on the gut microbiota.
Shambo Samrat Samajdar, Shatavisa Mukherjee, Rutul Gokalani, Supratik Bhattacharyya, Banshi Saboo, Shashank Joshi   +5 more
doaj   +1 more source

Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers.

, 2009
Vildagliptin is an orally effective, potent, and selective inhibitor of dipeptidyl peptidase IV (DPP-4) that improves glycemic control in patients with type 2 diabetes.
Hu, Pei, Yin, Qi, Deckert-Salva, Fabienne, Liu, Dongyang, He, Yan-Ling, Jiang, Ji, Dole, William, Kjems, Lise   +7 more
core  

Vildagliptin in clinical practice: a review of literature

, 2009
Vildagliptin is the second member of the DPP-IV inhibitor class of drugs licensed for the treatment of type 2 diabetes mellitus (T2DM). The novel action of these drugs has promoted a new outlook in the pathobiology of T2DM.
Soran, Handrean, Naveed Younis, Moulinath Banerjee, Handrean Soran, Banerjee, Moulinath; id_orcid, Younis, Naveed   +5 more
core   +1 more source

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

Vascular Health and Risk Management, 2008
Nasser MikhailEndocrinology Division, Olive View-UCLA Medical Center, David-Geffen School of Medicine, CA, USAAbstract: Sitagliptin and vildagliptin represent a new class of anti-diabetic agents that enhance the action of incretin hormones through ...
Nasser Mikhail
doaj  

Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).

, 2016
Aims To evaluate the real-world effectiveness of vildagliptin and vildagliptin/metformin, combined with patient engagement, on glycemic outcomes. Patient engagement included both clinicians’ engaging patients through education and counseling; and ...
Clemens, Andreas, Vancayzeele, Stefaan, MacDonald, Karen, Rezettee, Ingrid, Van Gaal, Luc, Abraham, Ivo, Hermans, Michel, De Meester, Lut, Yee, Brian, Denhaerynck, Kris, Rézette, Ingrid, Daci, Euis, Daci, Evis   +12 more
core   +1 more source

Effect of vildagliptin supplementation on pancreas islet cell

, 2011
Bu çalışmanın amacı, sıçanlara oral olarak uygulanan vildagliptinin adacık hücreleri üzerine etkilerini araştırmaktır. Sıçanlara 4 gün vildagliptin 100 mg/kg/gün verildikten sonra adacık hücreleri izole edildi.
Böyük, Gülbahar
core  

Proteomic changes related to actin cytoskeleton function in the skin of vildagliptin-treated mice [PDF]

Background: Vildagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i) is a widely used type 2 diabetes medication that is associated with an up-to 10-fold increased risk for the development of bullous pemphigoid (BP), an autoimmune skin disease.
Nätynki, Antti, Bergmann, Ulrich, Ohlmeier, Steffen, Tasanen, Kaisa, Kokkonen, Nina, Tuusa, Jussi   +5 more
core   +1 more source

The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.

, 2008
Vildagliptin is a potent, selective and reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for rapid inactivation of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). GLP-1 and GIP
Ahrén, Bo, Foley, J E
core   +1 more source

Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia

, 2008
Aim: This study was conducted to assess efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia.
Foley, J. E., P. M. Nilsson, A. Mari, Nilsson, Peter, Lalanne, G., S. Jauffret, Schweizer, A., J. E. Foley, G. Lalanne, A. Schweizer, W. A. Scherbaum, Mari, A., Jauffret, S., Scherbaum, W. A.   +13 more
core   +1 more source